Comenzo Raymond L, Zhou Ping, Fleisher Martin, Clark Bradly, Teruya-Feldstein Julie
Howard 802, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA.
Blood. 2006 May 1;107(9):3489-91. doi: 10.1182/blood-2005-10-4148. Epub 2006 Jan 26.
Investigators in the United Kingdom have shown that hereditary amyloidosis can be misdiagnosed as Ig light-chain (AL) amyloidosis because family history is an ineffective screen, and tissue staining used to type amyloid is unreliable. Misdiagnosis of AL can lead to inappropriate use of chemotherapy and failure to diagnose a hereditary disease. Over a 3-year period we sought to determine how often both possible sources of amyloidosis occurred in the same patient. We employed an algorithm based on established data and patterns of amyloidosis in order to focus the screening effort. Of 178 consecutive patients referred for amyloidosis, 54 were screened by polymerase chain reaction techniques with primers designed to detect transthyretin, apolipoprotein AI, apolipoprotein AII, fibrinogen Aalpha, and lysozyme variants. Three patients (6% of those screened and 2% of symptomatic patients) had both a monoclonal gammopathy and a hereditary variant. These results justify further study of screening for hereditary variants in patients with apparent AL, and highlight the need for practical techniques for identifying fibrils extracted from tissue.
英国的研究人员表明,遗传性淀粉样变性可能会被误诊为免疫球蛋白轻链(AL)淀粉样变性,因为家族病史作为筛查手段效果不佳,且用于淀粉样蛋白分型的组织染色不可靠。AL的误诊可能导致化疗使用不当以及未能诊断出遗传性疾病。在3年的时间里,我们试图确定同一患者同时出现这两种可能的淀粉样变性病因的频率。我们采用了一种基于已确立的数据和淀粉样变性模式的算法,以便集中筛查工作。在178例连续转诊的淀粉样变性患者中,54例通过聚合酶链反应技术进行筛查,所用引物旨在检测转甲状腺素蛋白、载脂蛋白AI、载脂蛋白AII、纤维蛋白原α和溶菌酶变体。3例患者(占筛查患者的6%,有症状患者的2%)既有单克隆丙种球蛋白病又有遗传性变体。这些结果证明有必要进一步研究对疑似AL患者进行遗传性变体筛查,并强调需要实用技术来鉴定从组织中提取的原纤维。